Back to search results

Radiation Therapy for Painful Bone Metastases

This study is comparing two different ways to give radiation therapy for painful bone metastases (cancer that has spread to the bones). One group will receive standard palliative radiation therapy, which is either 8 Gy in one session or 20 Gy in five sessions. The other group will receive stereotactic body radiation therapy (SBRT), which is either 16 Gy in one session or 27 Gy in three sessions. The main goal is to see if one type of radiation causes fewer side effects. You may be able to join if you are 18 or older, have a solid cancer that has spread to your bones, and are experiencing pain or discomfort at the treatment site. The study aims to enroll 220 participants.

Study design
This is a randomized study comparing two different radiation therapy approaches. It plans to enroll 220 participants.
What's involved
Pain response will be assessed at 2 weeks, 1 month, 3 months, and then every 3 months after treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06065449

A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases

Recruiting
PHASE3Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~220 participants
Updated 2026-01-14 on ClinicalTrials.gov
What's tested:Radiation Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over through study completion: an average of 1year

Conditions

Bone Metastases

Explore related trials

Metastatic Malignant Neoplasm in the Bone

NCT06065449

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • M D Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Quynh Nguyen, M D · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Quynh Nguyen, M D
[email protected]
(713) 563-2450
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with pathologic diagnosis of solid primary malignancy with any radiographic report of bone metastases including but not limited to plain x-ray, bone scan, CT scan, MRI, PET/CT scan, PSMA scan, PET fluciclovine scan. The exception is patients diagnosed with multiple myeloma are eligible.
Patients with any pain or discomfort at proposed treatment site.
Patients with life expectancy of 3 months or greater.
Patients able to complete pain assessment and quality of life surveys.
Patients with multiple osseous sites are eligible; however, should not treat more than three separate isocenters concurrently. Additional isocenters can be treated sequentially.
Patients with prior surgery for osseous metastases are eligible.
Patients age 18 years or older. Pediatric patients are usually enrolled on pediatric protocols. There are no adverse data available for patients \< 18 years of age treated with SBRT, therefore children are excluded from this study.
Patients may receive systemic therapy including chemotherapy, targeted therapy, immunotherapy, or other systemic agents up to and during radiation at treating physician's discretion per standard of care.
Patients must have adequate organ and marrow function as defined below:
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
The effects of radiation therapy on the developing human fetus are unknown. For this reason and because radiation therapy as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 2 weeks after completion of radiation therapy.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion

Patients with prior radiation therapy to the proposed treatment site.
Patient with current, un-treated cord compression at treatment site.
Patients with a radiographic or pathologic fracture at the proposed treatment site that is not mechanically stable. If this is stabilized mechanically or seen by orthopedic surgery, this site is eligible for enrollment and treated on protocol
Patients with metastases to hand and feet.
Patients with previously treated with radioactive isotope (e.g. Sr 89) within 30 days of randomization. This can have concomitant effects with radiation therapy.
Patients with spinal metastases along cervical, thoracic, or lumbar spine are not eligible. However, if the primary site invades the paraspinal or spine region, these are eligible.
Pregnant patients are not eligible.

What this trial measures

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion: an average of 1year